VERO Biotech Issued a Software Correction for Version 2.2.3
ATLANTA, July 22, 2021 /PRNewswire/ -- VERO Biotech LLC, an Atlanta, Georgia-based biotechnology company focused on saving lives, alleviating suffering, and improving the health economics of care, today announced that they voluntarily issued a correction to Software version 2.2.3 for GENOSYL DS devices, which is classified as a Class 1 recall.
- ATLANTA, July 22, 2021 /PRNewswire/ -- VERO Biotech LLC, an Atlanta, Georgia-based biotechnology company focused on saving lives, alleviating suffering, and improving the health economics of care, today announced that they voluntarily issued a correction to Software version 2.2.3 for GENOSYL DS devices, which is classified as a Class 1 recall.
- VERO Biotech worked with the FDA to issue the recall communication and take action to correct the issue.
- As of May 14, 2021, all GENOSYL DS devices affected by the recall were updated to the latest software version in the field.
- Nitric oxide is a powerful molecule proven to play a critical role in a broad array of biological functions.